Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Gov't to Introduce Medical Institution Selection System
July 5, 2010
- Explanations on Class 1 OTC Drugs Provided in Writing in Only 50% of Cases: Korosho Survey
July 5, 2010
- Subcommittee Restart Discussions for FY2012 NHI Pricing System Reform
July 5, 2010
- Vorinostat Designated as Orphan Drug
July 5, 2010
- Big J Pharmas Still Reel Them in
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
July 5, 2010
- Pfizer Creates Rare Disease Research Unit
June 28, 2010
- Korosho to Increase Transparency of NDA Review Process: Mr Nagatsuma
June 28, 2010
- Afinitor Extends PFS in Advanced pNET Patients in PIII: Novartis
June 28, 2010
- Astellas' Brazilian Affiliate Starts Operation
June 28, 2010
- FDA Orders Eisai, Sepracor to Stop Using Some Promotional Materials
June 28, 2010
- Kansai Bio-Promotion Allies with Flanders Bio
June 28, 2010
- ACRONET Invests in Chinese CRO NANDACRO
June 28, 2010
- CMIC Decides to Develop Sodium Phenylbutyrate
June 28, 2010
- NCCHD Considers Gene Therapy for Chronic Granuloma
June 28, 2010
- FTC Warns Nakazawa Ujike for Possible Anti-Monopoly Act Infringements
June 28, 2010
- Interim Analysis Confirms Safety of Tykerb in PIII for Stomach Cancer
June 28, 2010
- Merck Serono to Launch More Than 6 Products in 2012 Onward
June 28, 2010
- MCI to Launch New Detailing Tool Using iPad in July
June 28, 2010
- Cabazitaxel Increases OS in Prostate Cancer Patients
June 28, 2010
- Novo Launches Japan's 1st GLP-1 Agonist Victoza
June 28, 2010
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…